ChinaTrials Summit Announces 75 Global Pharma and Biotech Speakers to Present at Industry's Largest China Clinical

BEIJING, Jun 24 (MARKET WIRE) --
Over 75 global pharma and biotech experts will present at the annual
ChinaTrials: Global Clinical Development Conference & Exhibition in
Beijing this November 8-10, as the global biopharmaceutical industry
continues to shift its development activities to emerging regions to fuel
the next phase of growth.

"Interest in this year's ChinaTrials Summit is already well ahead of last
year's pace as it's becoming increasingly clear that China is the most
important emerging market for the life sciences industry," according to
Jon E. Liong, Managing Partner of Lychee Group, the organizer. "There's
been a dramatic increase in Western BioPharma companies interested in
conducting trials in China, and the number one reason is clearly time
savings. Drug developers want to get their medicines on the market the
fastest way possible without compromising on quality or safety, and China
is helping them do that."

In addition to time savings, the cost of conducting clinical studies in
China can be as much as 75% cheaper than the cost of conducting similar
trials in the West. This has drawn the attention of many small and
emerging biotech companies, who are particularly vulnerable to the current
global credit crisis, with less capital to fund the high costs of drug
development.

The conference's focus is unique, going beyond just China clinical
outsourcing topics and directly addressing the challenges facing the
hundreds of companies already doing drug development in China. Highlights
of the agenda include updates on the fast-changing SFDA guidelines, new
regulations on bridging studies for Japan/China, drug safety/quality
concerns, and in-depth coverage on conducting oncology trials in China.

The international speaking faculty, consisting of over 40 of the world's
largest companies includes Allergan, Amgen, Baxter, Bayer, Biogen Idec,
Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi-Sankyo,
GlaxoSmithKline, Johnson & Johnson, Lundbeck, Merck, Neuromed, Novartis,
Novo Nordisk, Pfizer, Roche, Sanofi-Aventis, Schering-Plough, and Wyeth.

All the major local and multinational CROs and clinical service providers
in China and Asia will also be in attendance including Quintiles,
Covance, Parexel, i3 Research, Phase Forward, Paramax International,
Excel Pharmastudies, George Clinical, and TigerMed.

To view the full conference agenda, visit www.chinatrialsevent.com or
contact Jon E. Liong at jon.liong@lycheegroup.com or call 1-732-917-0664.

ChinaTrials 2009 is organized by Lychee Group, LLC, a specialty media
company focused exclusively on China's life sciences industry.

Contact:
Jon E. Liong
Email Contact
1-732-917-0664

Copyright 2009, Market Wire, All rights reserved.

-0-